Asia · Regional markets · Business Standard

Dr Reddy's share price spurts 4% post Q2 earnings; analysts upgrade rating

Published by Business Standard · India 2 h ago

Analysts at Systematix Institutional Research and Elara Securities upgraded rating on Dr Reddy's Laboratories stock from 'Hold' to 'Buy' and 'Reduce' to 'Accumulate', respectively.

Read the full article on Business Standard Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.business-standard.com)

Also worth reading

CNBC-TV18

Sensex Today | Stock Market LIVE Updates: Nifty PSU Bk under pressure; Bank of India at 52-week low

Tech in Asia

Indian crypto exchange CoinSwitch launches anti-fraud drive

The Business Times

DFI Retail Group Q3 underlying profit up 17%; full-year guidance raised

The Straits Times Business

S’pore to raise retirement age to 65, re-employment age to 70 in 2029; expand flexi work for seniors

Yicai Global

China Vows to Stabilize New Births by Optimizing Housing Support Measures for Families

The Financial Express